Our data also indicate that a predominant input from SPIB correlates with a specific subgroup of primary ABC-DLBCL significantly associated with MYD88 mutation and a better prognosis in the context of currently standard therapy. Here, MYD88 is linked to diffuse large B-cell lymphoma.